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Background. Aspergillus and Mucorales species cause severe infections in patients after hematopoietic stem cell
transplantation (HSCT). Induction of antifungal CD4+ T-helper type 1 (Th1) immunity is an appealing strategy to
combat these infections. Immunotherapeutic approaches are so far limited because of a lack of antigens inducing
protective T cells, their elaborate production, and the need of targeting a broad spectrum of pathogenic fungi.
Methods. We examined the response to different Aspergillus fumigatus proteins in healthy individuals and pa-
tients after HSCT and compared rapid selection protocols for fungus-speciﬁc T cells based on CD137 or CD154
expression.
Results. The A. fumigatus proteins Crf1, Gel1, and Pmp20 induced strong Th1 responses in healthy individuals.
T cells speciﬁc for these antigens expanded in patients with active invasive aspergillosis, indicating their contribution
to infection control. Th1 cells speciﬁc for the 3 proteins can be selected with similar speciﬁcity within 24 hours, based
on CD137 or CD154 expression. These cells recognize naturally processed A. fumigatus and the multispeciﬁc T-cell
lines, directed against all 3 proteins, especially those selected by CD154, additionally cross-react to different Asper-
gillus and Mucorales species.
Conclusions. These ﬁndings may form the basis for adoptive T-cell transfer for prophylaxis or treatment in pa-
tients with these devastating infections.
Keywords. T-cell therapy; fungal infection; multispeciﬁc T cells; CD137 and CD154 expression; Aspergillus.
Aspergillus andMucorales species cause severe infections
in patients with leukemia and those who have undergone
allogeneic hematopoietic stem cell transplantation
(HSCT) [1, 2].
Antifungal prophylaxis or treatment in high-risk pa-
tients with prolonged neutropenia, T-cell suppression,
or graft-versus-host disease (GVHD) is often ineffective
owing to impaired host immunity and may result in the
emergence of uncommon or resistant molds. Treat-
ments are furthermore associated with drug interac-
tions, toxicity, and high costs [2]. Hence, treatment
approaches that restore or boost fungus-speciﬁc immu-
nity would be desirable.
Adoptive T-cell therapy using T-cell clones generated
by stimulation with Aspergillus fumigatus conidia in pa-
tients with invasive aspergillosis after haploidentical
HSCT was promising [3]. However, reproducibility is
difﬁcult because of the variation of stimuli and the elab-
orate production required for compliance with good
manufacturing practices.
Therefore, it is crucial to identify immunogenic pro-
teins and peptides in healthy individuals and patients
with invasive aspergillosis. This is challenging, however,
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because the A. fumigatus genome encodes for approximately
10 000 genes [4]. Until now, several immunogenic proteins
and T-cell epitopes have been characterized in healthy individ-
uals and mice, such as extracellular cell wall glucanases Crf1,
Crf2, Scw4 [5–9], 1,3-β-glucanosyl-transferase Gel1 [6, 8, 9],
GPI-anchored protein PST1 [9],mycelial catalase 1 [6, 7, 9], ser-
ine hydroxylmethyltransferase 2 [9], aspartic protease Pep1 [6,
8], enolase Aspf22 [9, 10], manganese superoxide dismutase
Sod2 [9, 10], and cytosolic peroxisomal peroxiredoxin Pmp20
(Asp f3) [9–11]. Only recently, T-cell responses to some of
these proteins have been shown to correlate with a beneﬁcial
outcome in patients with invasive aspergillosis [8, 12]. Further-
more, it would be desirable that these antigen-speciﬁc T cells
recognize additional clinically relevant molds.
To facilitate adoptive therapy for invasive aspergillosis, the
generation of T-cell products needs to be rapid, to be speciﬁc,
and to comply with GMP. The CliniMACS IFN-γ Cytokine
Capture System that has so far been successfully applied for
the generation of virus-speciﬁc T cells [13–15] shows limited
sensitivity for antigens with low T-cell precursor frequencies
[16]. Therefore, other T-cell activation markers that enable
selection of antigen-speciﬁc T cells with higher sensitivity
and irrespective of cytokine production may be more suit-
able. Selection methods based on activation-dependent ex-
pression of CD154 or CD137 have recently been shown to
be promising candidates [9, 17, 18]. Moreover, the Clini-
MACS CD137 isolation reagents were deemed in 2013 to
comply with GMP, but their clinical use has not yet been
demonstrated.
Here, we characterized the T-cell repertoire speciﬁc to differ-
ent Aspergillus-derived peptide pools and epitopes in healthy
individuals and patients after HSCT and compared the
CD154- and CD137-based isolation methods for speciﬁcity
and cross-reactive potential.
MATERIALS AND METHODS
Fungal Antigens
Aspergillus fumigatus lysate and Crf1, Gel1, and Pmp20 peptide
pools (Miltenyi Biotec) and custom-made peptide libraries of
Gel1 and Pmp20 (Proimmune) consisting of 111 and 40
15-mer peptides overlapped by 4 amino acids with a purity of
>70% and the Crf1/p41 FHTYTIDWTKDAVTW (JPT Peptide
Technologies) were reconstituted at 5 µg/µL in dimethyl sulfox-
ide (Sigma-Aldrich).
Generation of Heat-Inactivated Fungi
Aspergillus fumigatus strain D141 and clinical fungal isolates
were provided by Prof Dr Sven Krappmann (Medical Immunol-
ogy Campus Erlangen, Germany) and Dr Reno Frei (University
Hospital Basel, Switzerland), respectively, and were cultured
and heat inactivated as described elsewhere [5].
In Vitro Stimulation, Epitope Mapping, and CD137+ and CD154+
Selection
Blood specimens were obtained from healthy donors and pa-
tients after receipt of informed consent and in accordance
with a protocol approved by the Ethics Commission of North-
west and Central Switzerland. Isolation of peripheral blood
mononuclear cells (PBMCs) and generation of dendritic cells
(DCs) and macrophages were performed as published pre-
viously [5].
To generate antigen-speciﬁc T-cell lines, PBMCs were
stimulated for 7 days with A. fumigatus lysate (50 µg/mL),
Crf1, Pmp20, or Gel1 peptide pools (1 µg/peptide/mL) with
5 U/mL interleukin 2 (Proleukin, Chiron). CD3+/CD4+ and
CD3+/CD8+ cells were isolated by ﬂuorescence-activated cell
sorting from antigen-speciﬁc cell lines after 8 days and restim-
ulated with antigen-pulsed macrophages at a responder to stim-
ulator ratio of 5:1.
For CD137 and CD154 selection, 5–8 × 107 PBMCs in 4–5
mL of medium were stimulated with A. fumigatus lysate, Crf1,
Pmp20, Gel1, or all 3 peptide pools. A total of 1 µg/mL anti-
CD40 antibody was added for CD154-based selection (Miltenyi
Biotech). After 14 hours, cells were enriched by CD137+ or
CD154+ selection according to the manufacturers’ instructions
(Miltenyi Biotech). Up to 4 × 105 CD137+ or CD154+ cells were
cocultured with 50:1 γ-irradiated (35 cGy) autologous feeder
cells as published previously [16]. The cell lines were expanded
as described elsewhere [19].
Functionality Assays and Flow Cytometry
Interferon γ (IFN-γ), interleukin 17 (IL-17), interleukin 10 (IL-
10), and interleukin 4 (IL-4) enzyme-linked immunosorbent
spot (ELISPOT) analyses were performed according to the
manufacturers’ instructions, as published previously [16]. The
number of spot-forming cells was counted by an ELISPOT read-
er (Cellular Technologies).
For proliferation, PBMCs were labeled with carboxyﬂuores-
cein diacetate succinimidyl ester (CFSE; Invitrogen) according
to the manufacturer’s instructions and were stimulated with an-
tigens for 8 or 10 days. Intracellular cytokine (ICC) staining was
performed as described elsewhere [16]. Cells were stained with
Zombie-Aqua-Fixable-Viability Kit, anti-CD4-PaciﬁcBlue,
anti-CD8-allophycocyanin, anti-CD3-peridinin chlorophyll
protein antibodies (all Biolegend), and, for ICC, anti-IFN-γ-
phycoerythrin (PE) antibody (Miltenyi Biotech) and acquired
on a BD LSRFortessa system (BD Biosciences). Data were ana-
lyzed with FlowJo software vX.0.7.
The A. fumigatus Crf1/p41-speciﬁc major histocompatibility
complex class II tetramer DRB1*0401 FHTYTIDWTKDAVTW,
labeled with PE (Beckman Coulter), was used according to the
manufacturers’ instructions.
Granulocyte macrophage colony-stimulating factor (GM-
CSF), tumor necrosis factor α (TNF-α), IL-10, and transforming
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growth factor β (TGF-β) levels were determined in culture su-
pernatant after 48 hours stimulation (2 × 104 cells/200 µL/well
in 96-well plates) by enzyme-linked immunosorbent assay (all
R&D Systems) according to the manufacturers’ instructions.
The TGF-β level was determined with and without previous
activation.
To determine the cross-reactivity to different fungi, imma-
ture DCs were coincubated with heat-inactivated fungi over-
night and used to stimulate T-cell lines in an effector to
target ratio of 10:1 by ELISPOT analysis.
Alloreactivity was determined by [3H]-thymidine incorp-
oration. Autologous PBMCs and antigen-speciﬁc T-cell lines
(2 × 105 cells/well) were stimulated alone or with 2 different
third-party DCs at a responder to stimulator ratio of 10:1 for
96 hours. DNA synthesis was measured as published elsewhere
[16]. The counts per minute were determined using a liquid
scintillation counter.
Statistical Analysis
Data were analyzed by GraphPad Prism 6.0 (GraphPad Soft-
ware). The statistical tests used for statistical analyses are indi-
cated in the ﬁgure legends. P values of < .05 were considered
statistically signiﬁcant.
RESULTS
A. fumigatus Lysate and Peptide Pools of Crf1, Gel1, and Pmp20
Induce Similar and Predominant Th1 Responses
To identify immunogenic A. fumigatus antigens, we compared
A. fumigatus lysate, which complies with GMP, to commercially
available Crf1, Gel1, and Pmp20 peptide pools in healthy do-
nors (n≥ 8). Most of the donors showed IFN-γ production to
at least 2 of 3 tested peptide pools after 7 days of in vitro stim-
ulation, indicating that T cells speciﬁc for these antigens are
present in the healthy population. The response to peptide
pools was comparable to stimulation with A. fumigatus lysate,
except for Gel1, which had a lower stimulatory capacity.
There was only low IL-17, IL-4, and IL-10 production detected,
except for A. fumigatus lysate, which induced a higher IL-10 re-
sponse (Figure 1A).
Since recent publications indicated that, in addition to CD4+
Th1 cells, CD8
+ T cells induce protective antifungal immune re-
sponses [20, 21], we next determined the cellular source of IFN-
γ. As for Crf1 [5], most individuals showed a dominant CD4+
T-cell response. Only Pmp20 induced, in 2 of 6 donors, a CD8+
T-cell response comparable to or even higher than the CD4+ T-
cell response (Figure 1B). To verify these data, we determined
T-cell proliferation by CFSE staining, which conﬁrmed the pre-
dominance of CD4+ T-cell expansion toward all antigens
(Figure 1C).
In conclusion, in most healthy donors, the peptide pools
Crf1, Gel1, and Pmp20 induced a Th1 response that was
comparable in magnitude and cytokine proﬁle to stimulation
with A. fumigatus lysate.
Patients With Active Invasive Aspergillosis Respond to
A. fumigatus Antigens Irrespective of Absolute CD4+ T-Cell
Count and Show Expansion Over Time
To clarify whether T cells speciﬁc for A. fumigatus Crf1, Gel1,
and Pmp20 play a role during invasive aspergillosis, we ana-
lyzed the IFN-γ response to these antigens in 5 patients with
active invasive aspergillosis currently under control by antifun-
gal therapy and in 8 patients without any fungal infection or
antimold treatment before or after HSCT (Supplementary
Table 1). Samples were obtained from patients 5–19 months
after HSCT. Importantly, patients with active invasive aspergil-
losis showed high IFN-γ responses to all antigens, regardless of
absolute CD4+ T-cell counts and GVHD (Figure 2A), while pa-
tients without fungal infection showed comparable immune re-
sponses only with higher CD4+ T-cell counts (Figure 2B). IL-17
and IL-4 production was low in both groups (data not shown).
Furthermore, using the previously described HLA-DRB1*04
tetramer, 1 patient with well-controlled invasive aspergillosis
experienced expansion of Crf1/p41 tetramer-speciﬁc cells
from an undetectable level to 1.35% of CD4+ T cells over 10
weeks, which corresponded to an improvement of the pulmo-
nary lesion detected by computed tomography (Figure 2C).
In patients without invasive aspergillosis, as well as in a patient
with invasive aspergillosis with poor outcome, Crf1/p41-specif-
ic cells were not detectable (data not shown).
Taken together, T cells speciﬁc for Crf1, Gel1, and Pmp20
were detectable in peripheral blood specimens from patients
with well-controlled invasive aspergillosis, irrespective of
CD4+ T cell recovery and GVHD, and Crf1/p41-speciﬁc cells
expanded over time, concomitantly improving the fungal le-
sions, suggesting that these cells may contribute to the control
of invasive aspergillosis.
Identiﬁcation of Immunodominant Epitopes of Gel1 and Pmp20
Because of the promising results, we aimed to identify immuno-
dominant peptide epitopes of these proteins. As peptide epi-
topes for Crf1 have been previously characterized [5, 7, 12],
we focused on Gel1 and Pmp20. The mapping procedure is
shown in Supplementary Figure 1. Only 5 of 19 and 6 of 17
healthy donors recognized the most common epitopes for
Gel1 and Pmp20, respectively, and the overall responses were
lower than responses to the complete peptide pools (Table 1).
We therefore decided to use the complete peptide pools instead
of single epitopes for further experiments.
A. fumigatus–Speciﬁc T Cells Can Be Isolated on the Basis of
Activation-Dependent Surface Expression of CD137 and CD154
To generate pathogen-speciﬁc T cells for adoptive transfer,
rapid isolation methods for direct infusion are needed. We com-
pared the previously described CD154-based selection method
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to the CD137 selection method, recently judged to be in com-
pliance with GMP.
We performed the selections 14 hours after antigenic stimu-
lation, because surface expression of CD137 and CD154 was
highest after 14–24 hours, with decreased viability after 24
hours (data not shown).
T cells speciﬁc for A. fumigatus lysate, the peptide pools Crf1,
Gel1, and Pmp20 or the combination of all 3 peptide pools (C -
+ G + P) were enriched from PBMCs of 4 healthy donors. A
median of 1.6 × 105 cells for CD137 and 1.8 × 105 cells for
CD154 selection were isolated from 7 × 107 PBMCs, respective-
ly (Supplementary Figure 2A). The viability of the selected cells
was higher than 95% and similar for both selection methods.
There were no differences between A. fumigatus lysate and
the different peptide pools.
The percentage of cells expressing the activation marker after
isolation was signiﬁcantly higher for CD137, compared with
CD154 selection (median, 48.8% and 2.9%, respectively;
P ≤ .01 for all lines; Figure 3A and 3B). However, part of the
CD137 population had probably been enriched unspeciﬁcally,
because CD137 expression was detected in unstimulated con-
trols on up to 2.5% of lymphocytes (data not shown). As expect-
ed, CD154-based selection favored CD4+ T cells (median,
79.8%), whereas after CD137 selection only a median of
Figure 1. Healthy individuals show similar and predominant T-helper type 1 (Th1) responses to Aspergillus fumigatus lysate and peptide pools. A, Pe-
ripheral blood mononuclear cells (PBMCs) from healthy donors were prestimulated for 7 days with different A. fumigatus antigens, and the interferon γ (IFN-
γ), interleukin 17 (IL-17), interleukin 4 (IL-4), and interleukin 10 (IL-10) responses were determined by enzyme-linked immunosorbent spot (ELISPOT) analysis
after restimulation. The median IFN-γ responses to A. fumigatus lysate, Crf1, Gel1, and Pmp20 were 1140, 1088, 338, and 1488 spot-forming cells (SFCs)/
1 × 106 cells, respectively. The median IL-17 and IL-4 responses were ≤126 and ≤205 SFCs/1 × 106 cells, respectively. The median IL-10 response was
1102 SFCs/1 × 106 cells for lysate and ≤221 SFCs/1 × 106 cells for the peptide pools, respectively. Median responses of unstimulated controls for IFN-
γ, IL-17, IL-4, and IL-10 were 61 SFCs/1 × 106 cells (range, 0–433 SFCs/1 × 106 cells), 4 SFCs/1 × 106 cells (range, 0–235 SFCs/1 × 106 cells), 0 SFCs/
1 × 106 cells (range, 0–293 SFCs/1 × 106 cells), and 42.5 SFCs/1 × 106 cells (range, 0–771 SFCs/1 × 106 cells), respectively (n≥ 8). B, PBMCs from healthy
donors were prestimulated with A. fumigatus lysate or Gel1 or Pmp20 peptide pool. After 8 days, CD4+ and CD8+ T-cell subsets were isolated and indi-
vidually restimulated, and the IFN-γ response was determined by ELISPOT analysis. Median responses of unstimulated controls for CD4+ and CD8+ T cells
were 70 SFCs/1 × 106 cells (range, 0–920 SFCs/1 × 106 cells) and 48 SFCs/1 × 106 cells (range, 0–643 SFC/1 × 106 cells), respectively (n≥ 6). C, Carboxy-
ﬂuorescein diacetate succinimidyl ester–labeled PBMCs from healthy donors were stimulated with A. fumigatus lysate for 8 days or with Gel1 and Pmp20
peptide pool for 10 days. Proliferation of CD4+ and CD8+ T-cell subsets was determined by counterstaining with anti-CD3, anti-CD4, and anti-CD8 anti-
bodies. Median proliferation of unstimulated controls for CD4+ and CD8+ cells was 0.4% (range, 0.1%–1.5%) and 0.6% (range, 0.1%–1.7%), respectively
(n≥ 5). Data are shown after subtraction of values for the unstimulated control.
1254 • JID 2015:211 (15 April) • Stuehler et al
Figure 2. Hematopoietic stem cell transplant (HSCT) recipients with active invasive aspergillosis (IA) respond to Aspergillus fumigatus antigens irre-
spective of absolute CD4+ T-cell counts and Crf1/p41-speciﬁc cells show expansion over time. Peripheral blood mononuclear cells (PBMCs) from 5 HSCT
recipients with active IA (A) and 8 patients without fungal infection (B) 5–19 months after HSCT were prestimulated for 7 days with different A. fumigatus
antigens, and the interferon γ (IFN-γ) response was determined by enzyme-linked immunosorbent spot analysis after restimulation. Median responses of
unstimulated controls in patients with active IA and without fungal infection were 63 spot-forming cells (SFCs)/1 × 106 cells (range, 0–448 SFC/1 × 106 cells)
and 128 SFC/1 × 106 cells (range, 12–756 SFCs/1 × 106 cells, respectively. Data are shown after subtraction of the unstimulated control (n≥ 2 for patients
with IA). C, PBMCs obtained from a HLA-DRB1*04–positive HSCT recipient at different time points after diagnosis of IA were prestimulated with
A. fumigatus Crf1/p41 peptide for 7 days, and the frequency of Crf1/p41-speciﬁc T cells was determined by tetramer staining. Computed tomography
of the chest at the respective time points is shown in the panels below. Patients P1-P5, C1-C3, and C7 developed acute GVHD grade≥ 2 and were treated
with corticosteroids.
Multispeciﬁc Aspergillus T Cells • JID 2015:211 (15 April) • 1255
30.7% were CD4+ T cells, 13.7% were CD8+ T cells, and 56.5%
were CD4−CD8− T cells, including γδ T cells and natural killer
cells (Figure 3C and data not shown).
In conclusion, CD137- and CD154-based isolation allowed
selection of A. fumigatus lysate and peptide-speciﬁc T cells with
similar cell numbers and viability. The percentage of cells ex-
pressing CD137 was signiﬁcantly higher than of CD154, prob-
ably because of unspeciﬁc enrichment.
Aspergillus-Speciﬁc T-Cell Lines Show a Predominant Th1
Cytokine Proﬁle
The cell populations isolated by CD137 and CD154 expression
could be expanded by a median of 22-fold and 27-fold, respec-
tively (Supplementary Figure 2B), and the percentage of the dif-
ferent subpopulations remained unchanged for CD154-selected
lines but showed an increase of CD4+ T cells after CD137 selec-
tion (Figures 3C and 4A).
The expanded T-cell lines of all donors showed similar spe-
ciﬁcity, as evaluated by IFN-γ ICC staining, independent of an-
tigen and selection method, despite the higher purity after
CD137 selection conﬁrming unspeciﬁc expression (Figure 4B).
In all lines, the response was predominately mediated by CD4+
T cells, except in 2 donors, who showed high CD8+ T-cell re-
sponses in CD137-selected Pmp20 and Crf1 + Gel1 + Pmp20-
speciﬁc lines.
To further characterize the cytokine proﬁle we analyzed IL-
17, IL-4, GM-CSF, TNF-α, IL-10, and TGF-β secretion. The
cytokine responses were similar for all CD137- and CD154-
selected lines, and in addition to IFN-γ, all antigens induced
high production of IL-17 and GM-CSF and low production of
TNF-α, IL-10, and TGF-β (Figure 4C and 4D and data not
shown). The only difference was the higher IL-4 response in
the lines speciﬁc for A. fumigatus lysate, compared with the
other cell lines.
T-Cell Lines Generated With Crf1 + Gel1 + Pmp20 Remain
Multispeciﬁc
As the combination of all 3 peptide pools could potentially
cover a broader repertoire of Aspergillus-speciﬁc T cells than
the single pools, we investigated whether T-cell lines generated
with Crf1, Gel1, and Pmp20 were speciﬁc to all antigens. In-
deed, all multispeciﬁc T-cell lines showed speciﬁcity for all 3
peptide pools (Figure 4E), indicating limited antigenic compe-
tition and the feasibility of this combinatory approach.
Generated T-Cell Lines Respond to Naturally Processed Fungi
and Cross-react to Aspergillus and Mucorales Species and
Candida albicans
We further investigated the ability of the T-cell lines to respond
to naturally processed A. fumigatus. Overall, multispeciﬁc lines
showed higher IFN-γ and IL-17 responses to A. fumigatus hy-
phae than single-speciﬁc lines, and the CD154-selected lines re-
sponded better than the CD137 lines (Figure 5A and 5C).
As HSCT recipients are highly susceptible to other mold and
yeast infections, we challenged the expanded cell lines with clin-
ical isolates of different Aspergillus species (A. ﬂavus, A. terreus,
and A. niger), Scedosporium apiospermum, Scedosporium prolif-
icans, Fusarium solani, Rhizopus microsporus, Lichtheimia cor-
ymbifera, and Candida albicans. As shown in Figure 5A and 5C,
the CD154-generated multispeciﬁc lines showed high IFN-γ
and IL-17 responses to all Aspergillus species,Mucorales species,
and C. albicans, but responses to Fusarium and Scedosporium
species were not as strong. The CD137-selected cells showed
overall lower responses to A. fumigatus and other molds. By
contrast, all cell lines generated with lysate cross-reacted to all
fungi (Figure 5B and 5D).
In summary, multispeciﬁc T-cell lines, particularly those se-
lected by CD154, respond to naturally processed Aspergillus
species, Mucorales species, and C. albicans rendering them
highly applicable for clinical use.
Alloreactivity of Ex Vivo–Generated T-Cell Lines to Third-Party
DCs Is Signiﬁcantly Reduced
Because adoptive transfer of donor-derived T cells into HSCT
recipients may induce GVHD, we assessed their alloreactivity.
All lines, regardless of antigen or isolation method, showed sig-
niﬁcantly reduced alloreactivity to γ-irradiated, partially mis-
matched third-party DCs, compared with autologous PBMCs
(Figure 6).
Table 1. Epitope Mapping of Aspergillus fumigatus Gel1 and
Pmp20 Peptide Pools
Positive
Donors,
No. Gel1 Epitopes (n = 19) Pmp20 Epitopes (n = 17)
6 . . . p21 (VDVVAVLAYNDAYVM)
5 p34 (DVYLQYIFATVDAFA) p30 (ARFSKSIGWADEEGR)
p31 (KSIGWADEEGRTKRY)
4 p38 (YKNTLAFFSGNEVIN) p7 (KGEITACGIPINYNA)
p12 (DKKVILFALPGAFTP)
p14 (LPGAFTPVCSARHVP)
p22 (AVLAYNDAYVMSAWG)
p29 (SDPDARFSKSIGWAD)
p34 (KRYALVIDHGKITYA)
p40 (NHLEFSSAETVLKHL)
3 p39 (LAFFSGNEVINDGPS)
p59 (CDPSSFKTSGWDQKV)
p89 (WDVDNDALPAIPEPA)
p9 (IPINYNASKEWADKK)
p24 (YVMSAWGKANQVTGD)
p35 (LVIDHGKITYAALEP)
p36 (HGKITYAALEPAKNH)
p37 (TYAALEPAKNHLEFS)
Data are for 19 (Gel1) or 17 (Pmp20) healthy donors. Peripheral blood
mononuclear cells were stimulated for 7 days with the complete Gel1 or
Pmp20 peptide pools, and the response to different subpools were
determined by interferon γ enzyme-linked immunosorbent spot analysis.
Only subpools that induced a response of >100 spot-forming cells/1 × 106
cells were subsequently used in a second round of stimulation to determine
the response to single peptides. Only responses of >100 spot-forming cells/
1 × 106 cells were defined as relevant.
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DISCUSSION
In this study we show that A. fumigatus proteins Crf1, Gel1, and
Pmp20 are immunogenic and likely protective by inducing Th1-
cell responses in healthy individuals and patients with active in-
vasive aspergillosis after HSCT. Based on activation-dependent
expression of CD137 or CD154, these cells can be selected and
show similar speciﬁcity. Moreover, the multispeciﬁc CD154-
selected lines cross-react to the most relevant human-pathogen-
ic molds. Therefore, our results greatly foster adoptive T-cell
transfer for these problematic infections.
Clinical application of adoptive T-cell transfer strongly relies
on identiﬁcation of potent and safe fungal antigens. This is
challenging, however, owing to the high number of fungal pro-
teins. We focused on Crf1, Gel1, and Pmp20 because previous
studies indicated high immunogenicity in healthy individuals or
mice [5, 6, 10, 12, 22, 23], commercial availability, and potential
cross-reactivity to other human-pathogenic fungi [5, 6].We de-
tected IFN-γ responses primarily mediated by CD4+ Th1 cells to
at least 2 of 3 peptide pools in all healthy donors. A recent study
reported lower responses to Gel1 and Pmp20, compared with
Crf1, which may be due to the different experimental setups.
But these ﬁndings also support interindividual variability of
the immune responses [9].
Nevertheless, patients with active invasive aspergillosis re-
sponded similarly to these antigens, regardless of CD4+ T-cell
Figure 3. Aspergillus fumigatus–speciﬁc T cells can be isolated on the basis of activation-dependent expression of CD137 and CD154. A, Peripheral
blood mononuclear cells (PBMCs) from healthy donors were stimulated for 14 hours with different A. fumigatus antigens, and speciﬁc cells were isolated by
CD137 or CD154 positive selection. Shown are the positive fractions gated on lymphocytes from 1 representative donor (n = 4). B, The purity of CD137 and
CD154-positive fractions of 5 different antigens (n = 4). The purity of CD137-selected lines is signiﬁcantly higher than that of CD154-selected lines for all
antigens (P≤ .01, by 2-way analysis of variance with the Bonferroni multiple comparisons test). C, Phenotypic characterization of the isolated CD137+ and
CD154+ cells in the positive fractions. The abbreviation “C + G + P” indicates that all 3 antigens—Crf1, Gel1, and Pmp20—were used for stimulation.
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counts and GVHD, and the recovery of Crf1/p41-speciﬁc T cells
could be longitudinally monitored in a patient with improving
fungal lesions. These data are in line with 2 recent publications
showing the induction of IFN-γ responses to A. fumigatus Crf1
and Gel1 [8, 12] and additionally reveal that Pmp20-speciﬁc T
cells are also expanding in patients with invasive aspergillosis
with a beneﬁcial outcome, suggesting that these peptide-speciﬁc
T cells help to control the infection. These ﬁndings strengthen
the use of these candidate antigens for T-cell immunotherapy.
We further saw that Pmp20 induced high responses in CD8+ T
cells in some donors, which could be particularly relevant for
HSCT recipients early during immune recovery, when CD4+
T-cell reconstitution is frequently delayed [24].
To date, there is scarce knowledge about the required T-cell
epitopes and their HLA coverage that induce high numbers of
polyclonal CD4+ and CD8+ cells effective against mold infec-
tions. Similar to the approach used in the development of Ep-
stein-Barr virus–speciﬁc T cells [14], we intended to generate a
mixed peptide pool containing the most immunogenic epitopes
from different A. fumigatus proteins. However, as compared to
the previously identiﬁed Crf1 epitopes in humans [5, 7, 25], we
did not ﬁnd any highly immunogenic T-cell epitopes for
Pmp20 and Gel1.
The generation of a T-cell product for adoptive transfer
should be fast and simple, to be administered in a timely man-
ner to patients in need. To avoid ex vivo expansion, we com-
pared the CD154 method to the CD137 selection method,
which was recently found to comply with GMP but has not
yet been used in a clinical setting. The isolated cell number, vi-
ability, expansion potential, cytokine proﬁle, and alloreactivity
were comparable between all cell lines and independent of the
selection method or the antigen. Importantly, our T-cell lines
stimulated with all 3 peptide pools remained multispeciﬁc.
This is in line with our previous ﬁndings, in which activation-
dependent expression of CD154 allowed selection of T cells
speciﬁc for 3 viral and 2 fungal pathogens [16]. We isolated a
median of 0.25% of the starting cell fraction. A clinical scale
stimulation starting with 1 × 109 PBMCs would therefore yield
Figure 4. T-cell lines generated by CD137 or CD154 selection show similar cytokine responses after expansion, and Crf1, Gel1, and Pmp20-speciﬁc T
cells can be simultaneously expanded. A, Phenotypic characterization of CD137 or CD154-selected cell lines after 14 days of expansion (n = 4). B, The
percentage of interferon γ (IFN-γ)–producing cells in the CD4+, CD8+, and CD4−CD8− T-cell subsets, determined by intracellular cytokine staining after
restimulation of expanded T-cell lines. Median responses of unstimulated controls for CD4+, CD8+, and CD4−CD8− T cells were 0.33% (range, 0.03%–
4.7%), 0.43% (range, 0%–5.4%), and 0.3% (range, 0%–1.1%), respectively. The expanded cell lines were restimulated with their cognate antigens, and the
interferon γ (IFN-γ), interleukin 17 (IL-17), and interleukin 4 (IL-4) response were determined by enzyme-linked immunosorbent spot analysis (C), and the GM-
CSF response was determined by enzyme-linked immunosorbent assay (D). Median responses of unstimulated controls for IFN-γ, IL-17, and IL-4 were 430
spot-forming cells (SFCs)/1 × 106 cells (range, 20–3400 SFCs/1 × 106 cells), 60 SFCs/1 × 106 cells (range, 0–1950 SFCs/1 × 106 cells), and 5 SFCs/1 × 106
cells (range, 0–80 SFCs/1 × 106 cells), respectively, and for GM-CSF, the median response was 7.3 pg/mL (range, 0–51 pg/mL). E, Comparison of the spe-
ciﬁcity of T-cell lines stimulated with single peptide pools or the combination of all 3 peptide pools. Median response of unstimulated controls was 460
SFCs/1 × 106 cells (range, 20–3400 SFCs/1 × 106 cells). Data are shown after subtraction of the unstimulated control. The abbreviation “C + G + P” indicates
that all 3 antigens—Crf1, Gel1, and Pmp20—were used for stimulation.
1258 • JID 2015:211 (15 April) • Stuehler et al
around 2× 106–3 × 106 cells, which is comparable to the num-
bers used for antiviral T-cell transfer [13, 26, 27], suggesting
that the number of isolated CD137+ or CD154+ T cells could
be enough for the reconstitution of fungus-speciﬁc immunity
Figure 5. The interferon γ (IFN-γ) and interleukin-17 (IL-17) response of T-cell lines generated by CD137 and CD154 selection to different molds and
yeast. The IFN-γ (A and B) and interleukin 17 (IL-17; C and D) responses of peptide pool–speciﬁc (A and C) or lysate-speciﬁc (B and D) T-cell lines after
stimulation with different heat-inactivated molds and yeast were determined by enzyme-linked immunosorbent spot analysis. Median responses of unstimu-
lated controls for IFN-γ and IL-17 were 430 spot-forming cells (SFCs)/1 × 106 cells (range, 20–3400 SFCs/1 × 106 cells) and 60 SFCs/1 × 106 cells (range, 0–1950
SFCs/1 × 106 cells), respectively. The median responses are shown after subtraction of values for the unstimulated controls (n = 4). Abbreviations: A. ﬂavus,
Aspergillus ﬂavus; A. fumigatus, Aspergillus fumigatus; A. niger, Aspergillus niger; A. terreus, Aspergillus terreus; C. albicans, Candida albicans; F. solani,
Fusarium solani; L. corymbifera, Lichtheimia corymbifera; R. microsporus, Rhizopus microsporus; S. apiospermum, Scedosporium apiospermum; S. proliﬁcans,
Scedosporium proliﬁcans.
Figure 6. Aspergillus fumigatus–speciﬁc T-cell lines have signiﬁcantly reduced alloreactivity. CD137 or CD154-selected cell lines or autologous periph-
eral blood mononuclear cells (PBMCs) were coincubated with γ-irradiated, partially mismatched third-party dendritic cells, and the alloreactivity was de-
termined on the basis of 3H-thymidine incorporation in proliferating cells (P ≤ .01 for all lines, by 2-way analysis of variance with the Dunn multiple
comparisons test). Median responses of unstimulated controls for PBMC and cell lines were 751 counts per minute (range, 336–1043 counts per minute)
and 473 counts per minute (range, 272–1294 counts per minute), respectively. Data are shown after subtraction of values for the unstimulated control (n = 14).
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without the need of ex vivo expansion. These cells could be par-
ticularly suitable for lymphopenic patients after neutrophil en-
graftment, to support the effector functions of the neutrophils
and macrophages to prevent or treat invasive aspergillosis [28].
In line with the protective immunity of Th1 cells, the cytokine
proﬁle of CD137 and CD154-selected cell lines was dominated
by the Th1 cytokines IFN-γ and GM-CSF. The cell lines addi-
tionally produced IL-17, which is in general regarded as an
important cytokine in antifungal immunity [28]. In vitro–
stimulated PBMCs showed very low IL-17 production, indicat-
ing that the culture conditions during expansion probably
favored proliferation of the Th17 subset. Direct infusion of the
isolated cells should circumvent this imbalance. We further-
more excluded the presence of regulatory T cells, as previous re-
sults have postulated their enrichment after CD137 selection
[29, 30], and of Th2 cells, which are associated with antiinﬂam-
matory responses [23, 28].
The percentage of cells expressing the activation marker was
signiﬁcantly higher for CD137 selection than for CD154 selec-
tion, with median values of 48.8% and 2.9%, respectively. This is
probably due to low expression and fast downregulation of
CD154 leading to an underestimation of positive cells [16]
and to unspeciﬁc expression of CD137 causing overestimation,
indicating that activation marker expression cannot be equated
with antigen speciﬁcity. Compared with CD154 selection, which
strongly favors enrichment of CD4+ T cells [17], CD137-selected
cells were more diverse and additionally included high numbers
of natural killer cells and γδ T cells. These cells are increasingly
recognized to contribute to antifungal immunity [31–36], and re-
cent studies in patients with solid tumors or hematological ma-
lignancies demonstrated their safety [37].
In the last decade, infections with other Aspergillus and Mu-
corales species have increasingly been reported [38–40]. We
have previously shown that CD4+ T cells speciﬁc for the A. fu-
migatus Crf1/p41 epitope confer cross-reactivity to C. albicans
[5], and a potential cross-reactivity of Gel1 was suggested in a
mouse model [6]. In particular, T-cell lines speciﬁc for all 3 an-
tigens and selected by CD154 expression not only efﬁciently
recognized naturally processed A. fumigatus, but also cross-re-
acted to different clinically relevant Aspergillus species and the
Mucorales species, Rhizopus microsporus, and Lichtheimia cor-
ymbifera, suggesting that adoptively transferred T cells could
very likely protect the recipients against a variety of fungal in-
fections. It remains unclear, however, which epitopes confer
cross-reactivity, as BLAST analysis indicated only limited genet-
ic similarity between these fungi.
Compared with the peptide pools, A. fumigatus lysate–speciﬁc
lines cross-reacted to all tested molds and yeast. This may be
explained by the fact that lysate contains various cell wall com-
ponents that are less diverse between different fungal species,
compared with protein antigens [41]. On the other hand,
some cell wall components, such as galactosaminogalactan,
are able to actively inhibit the induction of protective responses
[42]. This might also explain the high level of IL-10 secretion in
PBMCs stimulated with fungal lysate, which could be mediated
by T cells as well as monocytes, and the higher IL-4 response in
lysate-speciﬁc as compared to peptide-speciﬁc lines. The im-
mune response induced by lysate is therefore less predictable
and could potentially reduce the efﬁcacy of a T-cell product.
By contrast, the combination of all 3 peptide pools is highly
suitable for the generation of mold-speciﬁc T cells, because it
probably covers a wider range of HLA types, induces higher
numbers of polyclonal CD4+ and CD8+ T cells, confers cross-
reactivity to different fungi, and appears to be safe.
In conclusion, T cells speciﬁc for A. fumigatus Crf1, Gel1,
and Pmp20 selected by activation-dependent CD137 or CD154
expression may form the basis for adoptive T-cell transfer for
prophylaxis in high-risk patients or for treatment in patients
with refractory mold infections.
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